229 related articles for article (PubMed ID: 30968338)
1. The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence".
Pivonello R; Arnaldi G; Scaroni C; Giordano C; Cannavò S; Iacuaniello D; Trementino L; Zilio M; Guarnotta V; Albani A; Cozzolino A; Michetti G; Boscaro M; Colao A
Endocrine; 2019 Jun; 64(3):657-672. PubMed ID: 30968338
[TBL] [Abstract][Full Text] [Related]
2. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study.
Albani A; Ferraù F; Ciresi A; Pivonello R; Scaroni C; Iacuaniello D; Zilio M; Guarnotta V; Alibrandi A; Messina E; Boscaro M; Giordano C; Colao A; Cannavo S
Endocrine; 2018 Jul; 61(1):118-124. PubMed ID: 29383677
[TBL] [Abstract][Full Text] [Related]
6. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.
Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R
Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263
[TBL] [Abstract][Full Text] [Related]
7. The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.
Simeoli C; Ferrigno R; De Martino MC; Iacuaniello D; Papa F; Angellotti D; Pivonello C; Patalano R; Negri M; Colao A; Pivonello R
J Endocrinol Invest; 2020 Jan; 43(1):57-73. PubMed ID: 31313243
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Opposite Tumoral and Hormonal Responses to Low-dose Pasireotide in Cushing's Disease.
Serban AL; Zampetti B; Saladino A; Favero V; Chiodini I; Cozzi R
Endocr Metab Immune Disord Drug Targets; 2024; 24(7):845-849. PubMed ID: 37937561
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
12. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW; Fleseriu M; Newell-Price J; Petersenn S; Pivonello R; Kandra A; Pedroncelli AM; Biller BM
Endocrine; 2016 Nov; 54(2):516-523. PubMed ID: 27209465
[TBL] [Abstract][Full Text] [Related]
13. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
14. Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M; Bertherat J; Findling J; Fleseriu M; Atkinson AB; Petersenn S; Schopohl J; Snyder P; Hughes G; Trovato A; Hu K; Maldonado M; Biller BM
Pituitary; 2014 Aug; 17(4):320-6. PubMed ID: 23943009
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MacKenzie Feder J; Bourdeau I; Vallette S; Beauregard H; Ste-Marie LG; Lacroix A
Pituitary; 2014 Dec; 17(6):519-29. PubMed ID: 24287689
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study.
Manetti L; Deutschbein T; Schopohl J; Yuen KCJ; Roughton M; Kriemler-Krahn U; Tauchmanova L; Maamari R; Giordano C
Pituitary; 2019 Oct; 22(5):542-551. PubMed ID: 31440946
[TBL] [Abstract][Full Text] [Related]
18. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A; Bronstein MD; Schopohl J; Delibasi T; Salvatori R; Li Y; Barkan A; Suzaki N; Tauchmanova L; Ortmann CE; Ravichandran S; Petersenn S; Pivonello R
J Endocrinol Invest; 2020 Nov; 43(11):1613-1622. PubMed ID: 32385851
[TBL] [Abstract][Full Text] [Related]
19. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
Webb SM; Ware JE; Forsythe A; Yang M; Badia X; Nelson LM; Signorovitch JE; McLeod L; Maldonado M; Zgliczynski W; de Block C; Portocarrero-Ortiz L; Gadelha M
Eur J Endocrinol; 2014 Jul; 171(1):89-98. PubMed ID: 24760537
[TBL] [Abstract][Full Text] [Related]
20. The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.
Trementino L; Zilio M; Marcelli G; Michetti G; Barbot M; Ceccato F; Boscaro M; Scaroni C; Arnaldi G
Endocrine; 2015 Sep; 50(1):154-61. PubMed ID: 25500791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
